Core Laboratories Gelecekteki Büyüme
Future kriter kontrolleri 3/6
Core Laboratories kazanç ve gelirinin sırasıyla yıllık 33.1% ve 2.4% oranında artması tahmin edilirken, EPS'nin yıllık 31.8% oranında büyümesi bekleniyor.
Anahtar bilgiler
33.1%
Kazanç büyüme oranı
31.78%
EPS büyüme oranı
| Energy Services kazanç büyümesi | 22.6% |
| Gelir büyüme oranı | 2.4% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 19 Aug 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Analiz Makalesi • Aug 07
Core Laboratories' (NYSE:CLB) Weak Earnings May Only Reveal A Part Of The Whole Picture
Core Laboratories Inc.'s ( NYSE:CLB ) recent weak earnings report didn't cause a big stock movement. Our analysis...
Anlatı Güncellemesi • Jun 22
CLB: Refined Assumptions Will Support Undervalued Shares And Future P/E
Analysts have reaffirmed their $22.00 price target on Core Laboratories, citing updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E that refine but do not materially alter their prior valuation view. What’s in the News for Core Laboratories No recent Core Laboratories specific news items were identified in the provided sources.
Anlatı Güncellemesi • Jun 07
CLB: Future Middle East Recovery Will Support Reservoir Description Led Upside Potential
Analysts have revised their price target for Core Laboratories to $16.33, with the change supported by updated assumptions around a 7.59% discount rate, 1.85% revenue growth, a 6.35% profit margin, and a future P/E of 24.86x. What's in the News Core Laboratories revised its earnings guidance for the first quarter of 2026, indicating that revenue and earnings are expected to be below the guidance issued on 4 February 2026.Anlatı Güncellemesi • May 23
CLB: Middle East Disruptions Will Shape Undervalued Shares And Future P/E
Analysts have kept their $22.00 price target for Core Laboratories unchanged, citing updated assumptions that include a slightly higher discount rate and revenue growth outlook, along with a marginally lower profit margin and P/E expectation. What's in the News Core Laboratories revised its first quarter 2026 guidance, now expecting revenue between US$119,000,000 and US$123,000,000, operating income ex-items of US$5,700,000 to US$7,100,000, and EPS ex-items of US$0.05 to US$0.07, citing impacts from geopolitical conflict in the Middle East, client project delays, travel limits, and supply chain disruptions (Key Developments).Anlatı Güncellemesi • Apr 28
CLB: Fair Outlook Balances Middle East Disruptions And Governance Changes
Analysts have raised their price target on Core Laboratories from about $14.00 to roughly $16.33, citing updated views on fair value, discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000 and EPS, ex items, of US$0.05 to US$0.07 for the period (Key Developments).Anlatı Güncellemesi • Apr 14
CLB: Fair Value View Will Rely On Middle East Risk And P/E Assumptions
Analysts have raised their price target on Core Laboratories from $18 to $22, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple as key drivers of the change. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000, operating income ex items of US$5,700,000 to US$7,100,000, and Earnings Per Share ex items of US$0.05 to US$0.07 (Key Developments).Seeking Alpha • Mar 26
Core Laboratories: Profit Margins Are Too Small To Get Excited About
Summary Core Laboratories remains a HOLD due to persistently low profit margins and unattractive free cash flow yields. Recent Middle East disruptions have significantly impacted CLB’s higher-margin Reservoir Description segment, prompting a downward revision of Q1 EPS guidance. CLB’s capital allocation will continue with a 50/50 split between debt reduction and shareholder returns, targeting leverage below 1.0x. The current valuation at 14x EBITDA is not justified given flat revenues, low margins, and increased operational risks. The stock is valued at low single digit free cash flow yields. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jan 26
CLB: Fair Value View Will Rely On Stable Margins And P/E Assumptions
Analysts held their price target on Core Laboratories steady at US$18.00, citing only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their overall view of the company. Valuation Changes Fair Value: Held steady at US$18.00, indicating no change in the core valuation output.Anlatı Güncellemesi • Jan 11
CLB: Fair Value View Will Rely On Stabilizing Margins And EPS
Analysts kept their Core Laboratories fair value estimate around $18.00. The updated price target mainly reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E rather than a major shift in their view of the stock.Anlatı Güncellemesi • Dec 14
CLB: Future Earnings And Margins Are Expected To Gradually Stabilize
Analysts have modestly reduced their price target on Core Laboratories by 1 dollar to 18 dollars. This reflects a slightly lower fair value despite improved expectations for revenue growth, profit margin, and a less demanding future price to earnings multiple.Analiz Makalesi • Nov 21
A Look At The Fair Value Of Core Laboratories Inc. (NYSE:CLB)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$14.45 Core...Anlatı Güncellemesi • Sep 10
Middle East And Asia Pacific Markets Will Secure Energy Success
With both the discount rate and future P/E ratio remaining essentially stable, the consensus analyst price target for Core Laboratories was unchanged at $14.00. What's in the News Core Laboratories issued third quarter 2025 guidance, expecting revenue of $127.5–134.5 million, operating income of $13.6–16.2 million, operating margin of approximately 11%, and EPS of $0.18–0.22.Analiz Makalesi • Sep 10
Core Laboratories Inc.'s (NYSE:CLB) 25% Jump Shows Its Popularity With Investors
Core Laboratories Inc. ( NYSE:CLB ) shareholders would be excited to see that the share price has had a great month...Analiz Makalesi • Jul 24
We Think Core Laboratories (NYSE:CLB) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Jul 03
Core Laboratories (NYSE:CLB) Will Be Hoping To Turn Its Returns On Capital Around
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...Analiz Makalesi • Jun 12
Is There An Opportunity With Core Laboratories Inc.'s (NYSE:CLB) 49% Undervaluation?
Key Insights The projected fair value for Core Laboratories is US$23.89 based on 2 Stage Free Cash Flow to Equity Core...Analiz Makalesi • Apr 04
Core Laboratories Inc.'s (NYSE:CLB) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 20x Core Laboratories Inc. ( NYSE:CLB ) may be sending bearish signals at...Analiz Makalesi • Jan 21
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 27% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$27.00 Core...Analiz Makalesi • Jan 03
Core Laboratories Inc. (NYSE:CLB) Not Lagging Market On Growth Or Pricing
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...Analiz Makalesi • Dec 09
Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Analiz Makalesi • Nov 12
Is Core Laboratories (NYSE:CLB) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Yeni Anlatı • Sep 24
New Product Launches And Deleveraging To Propel Growth Amidst Geopolitical Challenges
Diversification in geographical markets and services strengthens revenue by expanding market presence and targeting regions with growing demand.Analiz Makalesi • Sep 19
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?
Key Insights The projected fair value for Core Laboratories is US$29.58 based on 2 Stage Free Cash Flow to Equity...Analiz Makalesi • Aug 14
What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Analiz Makalesi • Jul 15
We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Jun 25
These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Analiz Makalesi • May 02
It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year
Key Insights Core Laboratories' Annual General Meeting to take place on 8th of May Salary of US$886.9k is part of CEO...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2027 | 535 | 36 | 49 | 63 | 3 |
| 12/31/2026 | 510 | 20 | 22 | 40 | 3 |
| 6/30/2026 | 519 | 24 | 11 | 28 | N/A |
| 3/31/2026 | 525 | 29 | 18 | 34 | N/A |
| 12/31/2025 | 527 | 30 | 22 | 37 | N/A |
| 9/30/2025 | 518 | 32 | 34 | 50 | N/A |
| 6/30/2025 | 517 | 30 | 39 | 54 | N/A |
| 3/31/2025 | 518 | 28 | 44 | 58 | N/A |
| 12/31/2024 | 524 | 31 | 43 | 56 | N/A |
| 9/30/2024 | 523 | 26 | 44 | 55 | N/A |
| 6/30/2024 | 514 | 24 | 30 | 42 | N/A |
| 3/31/2024 | 511 | 38 | 22 | 33 | N/A |
| 12/31/2023 | 510 | 37 | 14 | 25 | N/A |
| 9/30/2023 | 509 | 41 | 9 | 19 | N/A |
| 6/30/2023 | 510 | 39 | 15 | 25 | N/A |
| 3/31/2023 | 503 | 24 | 6 | 16 | N/A |
| 12/31/2022 | 490 | 19 | 15 | 25 | N/A |
| 9/30/2022 | 487 | 15 | 6 | 19 | N/A |
| 6/30/2022 | 479 | 9 | 11 | 25 | N/A |
| 3/31/2022 | 477 | 10 | 21 | 34 | N/A |
| 12/31/2021 | 470 | 20 | 23 | 37 | N/A |
| 9/30/2021 | 459 | 31 | 5 | 18 | N/A |
| 6/30/2021 | 446 | 33 | 15 | 26 | N/A |
| 3/31/2021 | 443 | 19 | 32 | 44 | N/A |
| 12/31/2020 | 487 | -97 | 45 | 58 | N/A |
| 9/30/2020 | 530 | -101 | 77 | 91 | N/A |
| 6/30/2020 | 598 | -80 | 79 | 96 | N/A |
| 3/31/2020 | 651 | -55 | N/A | 86 | N/A |
| 12/31/2019 | 668 | 94 | N/A | 90 | N/A |
| 9/30/2019 | 685 | 92 | N/A | 106 | N/A |
| 6/30/2019 | 694 | 90 | N/A | 104 | N/A |
| 3/31/2019 | 700 | 96 | N/A | 114 | N/A |
| 12/31/2018 | 701 | 80 | N/A | 112 | N/A |
| 9/30/2018 | 698 | 93 | N/A | 120 | N/A |
| 6/30/2018 | 678 | 91 | N/A | 126 | N/A |
| 3/31/2018 | 661 | 87 | N/A | 118 | N/A |
| 12/31/2017 | 648 | 81 | N/A | 124 | N/A |
| 9/30/2017 | 627 | 75 | N/A | 102 | N/A |
| 6/30/2017 | 608 | 71 | N/A | 107 | N/A |
| 3/31/2017 | 598 | 67 | N/A | 116 | N/A |
| 12/31/2016 | 590 | 65 | N/A | 132 | N/A |
| 9/30/2016 | 628 | 64 | N/A | 158 | N/A |
| 6/30/2016 | 682 | 81 | N/A | 167 | N/A |
| 3/31/2016 | 738 | 99 | N/A | 186 | N/A |
| 12/31/2015 | 798 | 115 | N/A | 219 | N/A |
| 9/30/2015 | 893 | 166 | N/A | 268 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: CLB 'nin tahmini kazanç büyümesi (yıllık 33.1% ) tasarruf oranının ( 3.7% ) üzerindedir.
Kazançlar ve Piyasa: CLB şirketinin kazançlarının (yıllık 33.1% ) US pazarından (yıllık 17.3% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: CLB şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.
Gelir ve Pazar: CLB şirketinin gelirinin (yıllık 2.4% ) US pazarından (yıllık 13.5% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: CLB şirketinin gelirinin (yıllık 2.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: CLB 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/10 08:22 |
| Gün Sonu Hisse Fiyatı | 2026/09/10 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Core Laboratories Inc. 30 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| James West | Barclays |
| Nicholas Green | Bernstein |
| Saurabh Pant | BofA Global Research |